Placebo controlled comparison of acute effects of ebastine and clemastine on performance and EEG.
The effects of single oral doses of 10 and 20 mg ebastine were compared with placebo and 2 mg clemastine in a double-blind cross-over study in 16 healthy male volunteers. Clemastine produced the known pattern of changes, namely impairment of psychomotor performance, drowsiness, and a selective effect on cognitive processes. Earlier encoding in a perceptual stage was slowed whereas abstract classification processes were not affected. Electrophysiological measures of vigilance showed a general decrease in vigilance especially 2.5 and 4.5 h after dosing. In contrast at no time was any effect of ebastine different from that of the placebo. Ebastine 10 and 20 mg differed positively from clemastine in its effect on pursuit tracking, subjective rating of drowsiness and general discomfort. Ebastine 10 mg also differed positively from clemastine in the EEG features of vigilance. It is concluded that 10 and 20 mg ebastine were free from sedative adverse effects.
Department of Clinical Pharmacology, Laboratory for Experimental Psychopharmacology, E. Merck, Darmstadt, FRG.
H
H
Hopes
G H
GH
Meuret
W
W
Ungethüm
G
G
Leopold
H
H
Wiemann
D000328:Adult; D002090:Butyrophenones / Q000494:pharmacology*; D002974:Clemastine / Q000494:pharmacology*; D003071:Cognition / Q000187:drug effects; D004311:Double-Blind Method; D004569:Electroencephalography / Q000187:drug effects*; D006634:Histamine H1 Antagonists / Q000494:pharmacology*; D006801:Humans; D008297:Male; D010880:Piperidines / Q000494:pharmacology*; D011597:Psychomotor Performance / Q000187:drug effects*; D012016:Reference Values; D012890:Sleep / Q000187:drug effects; D011795:Surveys and Questionnaires; D014851:Wakefulness / Q000187:drug effects
D002090:Butyrophenones; D006634:Histamine H1 Antagonists; D010880:Piperidines; D002974:Clemastine; C058249:ebastine